Heart failure & cardiomyopathies
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF
An erratum to this article was published (JAMA Cardiol, 1 Jun 2025 ↗)
Authors' conclusion
Results of the FINEARTS-HF randomized clinical trial demonstrate that the PREDICT-HFpEF models performed well in terms of calibration and discrimination. Baseline risk did not modify the benefit of finerenone.
Study context
- Population
- Adults ≥40 years with symptomatic heart failure (HF) and LVEF ≥40% (HFmrEF or HFpEF)
- Participants
- 6,001 adults
- Comparison
- Finerenone vs placebo across PREDICT-HFpEF risk quintiles; validation of PREDICT-HFpEF models
- Primary endpoint
- PREDICT-HFpEF model performance (Harrell C statistic) for CV death or HF hospitalisation, CV death and all-cause death; finerenone effect by risk quintile
- Follow-up
- 2 years
Methodological detailsmulticentre, 653 sites in 37 countries
- Multicentre
- 653 sites in 37 countries
Primary result
As reported in the abstract
PREDICT-HFpEF discrimination (C statistic)
C statistic, CV death or HF hospitalisation
0.71
95% CI 0.69–0.72
C statistic, CV death
0.68
95% CI 0.66–0.71
C statistic, all-cause death
0.69
95% CI 0.67–0.71
Risk of composite outcomes, highest vs lowest risk quintile
≈8- to 10-fold higher
Original publication
Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF. JAMA Cardiol. Published 1 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →